This website is intended for healthcare professionals
Respiratory Handbook

The professional's guide to product selection

Products

Mini-Wright Peak Flow Windmill Trainer

The Windmill Trainer has been designed as a training aid to develop good peak expiratory flow (PEF) technique in:
• children
• elderly
• people with language or learning difficulties.

The windmill adds an element of fun, particularly for children.

Mini-Wright Standard Range Peak Flow Meter

  • Scale ranges from 60–800 l/min
  • Scale available in three colours for easy readings Hand calibrated for accuracy
  • Easy to clean, lightweight and portable
  • Suitable for both home and clinic use, also suitable for most adults and children
  • Available in three scales: the standard European Union scale, the American Thoracic Society scale, and the old Wright McKerrow scale used in clinical trials
  • Supplied complete with instructions for use, a patient self-monitoring chart and sterilisable mouthpiece.

Stockist: Medisave

Mizolastine - Sanofi

Non-sedating antihistamine.

For symptomatic relief of allergy, such as hay fever, or urticaria.

• Over 12 years: 10 mg, once daily.

Mometasone furoate - AAH Pharmaceuticals Ltd

Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.

Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.

Mometasone furoate - Alliance Healthcare (Distribution) Ltd

Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.

Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.

Mometasone furoate - Almus Pharmaceuticals Ltd

Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.

Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.

Mometasone furoate - DE Pharmaceuticals

Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.

Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.

Mometasone furoate - Medihealth (Northern) Ltd

Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.

Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.

Mometasone furoate - NorthStar Healthcare Unlimited Company

For prophylaxis of asthma by inhalation of powder
• Child 12–17 years: Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained.
• Adult: Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained.

For prophylaxis of severe asthma by inhalation of powder
• Child 12–17 years: Increased if necessary up to 400 micrograms twice daily.
• Adult: Increased if necessary up to 400 micrograms twice daily.

Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.

Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.

Mometasone furoate - Organon Pharma (UK) Ltd

For prophylaxis of asthma by inhalation of powder
• Child 12–17 years: Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained.
• Adult: Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained.

For prophylaxis of severe asthma by inhalation of powder
• Child 12–17 years: Increased if necessary up to 400 micrograms twice daily.
• Adult: Increased if necessary up to 400 micrograms twice daily.

Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.

Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.